Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis

References

• CompstonAColesAMultiple sclerosisLancet200235993131221123111955556
   PubMed Web of Science ®Google Scholar
• RolakLAMultiple sclerosis: it’s not the disease you thought it wasClin Med Res200311576015931287
   PubMedGoogle Scholar
• National Multiple Sclerosis SocietyJust the facts (2008–2009) Available from: http://www.nationalmssociety.org/about-multiple-sclerosis/what-we-know-about-ms/what-is-ms/index.aspx. Accessed Dec 8 2010.
   Google Scholar
• BainbridgeJLRieckmannPMultiple sclerosisDiPiroJTTalbertRYeeGMatzkeGPharmacotherapy: a pathophysiologic approachNew YorkMcGraw-Hill Medical2008913926
   Google Scholar
• RopperAHSamuelsMAMultiple sclerosis and allied demyelinating diseases Adams and Victor’s principles of neurology9th edNew YorkMcGraw-Hill Medical2009771796
   Google Scholar
• IFNB Multiple Sclerosis GroupInterferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study GroupNeurology19934346556618469318
   PubMed Web of Science ®Google Scholar
• JacobsLDCookfairDLRudickRAIntramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)Ann Neurol19963932852948602746
   PubMed Web of Science ®Google Scholar
• JohnsonKPBrooksBRFordCCSustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study GroupMult Scler20006425526610962546
   PubMed Web of Science ®Google Scholar
• PRISMSRandomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study GroupLancet19983529139149815049820297
   PubMed Web of Science ®Google Scholar
• World Health OrganizationAdherence to long-term therapies: Evidence for action Available from: http://www.who.int/chp/knowledge/publications/adherence_full_report.pdf. Accessed Dec 8 2010.
   Google Scholar
• New England Health Care InstituteThinking outside the pillbox: A system-wide approach to improving patient medication adherence for chronic disease Available from: http://www.nehi.net/publications/44/thinking_outside_the_pillbox_a_systemwide_approach_to_improving_patient_medication_adherence_for_chronic_disease. Accessed Dec 8 2010.
   Google Scholar
• CramerJARoyABurrellAMedication compliance and persistence: terminology and definitionsValue Health2008111444718237359
   PubMed Web of Science ®Google Scholar
• SteinbergSCFarisRJChangCFChanATankersleyMAImpact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort studyClin Drug Investig201030289100
   PubMed Web of Science ®Google Scholar
• TreadawayKCutterGSalterAFactors that influence adherence with disease-modifying therapy in MSJ Neurol2009256456857619444532
   PubMed Web of Science ®Google Scholar
• DevonshireVLapierreYMacdonellRThe Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosisEur J Neurol2010614 [Epub ahead of print]
   Google Scholar
• AndradeSEKahlerKHFrechFChanKAMethods for evaluation of medication adherence and persistence using automated databasesPharmacoepidemiol Drug Saf200615856557416514590
   PubMed Web of Science ®Google Scholar
• TremlettHvandMIPittasFAdherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing dosesPharmacoepidemiol Drug Saf200817656557618395883
   PubMed Web of Science ®Google Scholar
• HaynesRBMcDonaldHPGargAXHelping patients follow prescribed treatment: clinical applicationsJAMA2002288222880288312472330
   PubMed Web of Science ®Google Scholar
• BruceJMHancockLMLynchSGObjective adherence monitoring in multiple sclerosis: initial validation and association with self-reportMult Scler201016111212019995835
   PubMed Web of Science ®Google Scholar
• TremlettHLOgerJInterrupted therapy: stopping and switching of the beta-interferons prescribed for MSNeurology200361455155412939437
   PubMed Web of Science ®Google Scholar
• RioJPorcelJTellezNFactors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosisMult Scler200511330630915957512
   PubMed Web of Science ®Google Scholar
• ClericoMBarberoPContessaGFerreroCDurelliLAdherence to interferon-beta treatment and results of therapy switchingJ Neurol Sci200725912104108
   Web of Science ®Google Scholar
• O’RourkeKEHutchinsonMStopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patternsMult Scler2005111465015732266
   PubMed Web of Science ®Google Scholar
• QuanHSundararajanVHalfonPCoding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative dataMed Care200543111130113916224307
   PubMed Web of Science ®Google Scholar
• CharlsonMEPompeiPAlesKLMacKenzieCRA new method of classifying prognostic comorbidity in longitudinal studies: development and validationJ Chronic Dis19874053733833558716
   PubMedGoogle Scholar
• DeyoRACherkinDCCiolMAAdapting a clinical comorbidity index for use with ICD-9-CM administrative databasesJ Clin Epidemiol19924566136191607900
   PubMed Web of Science ®Google Scholar
• OllendorfDAJilinskaiaEOleen-BurkeyMClinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care populationJ Managed Care Pharm200286469476
   Google Scholar
• ReynoldsMWStephenRSeamanCRajagopalanKPersistence and adherence to disease modifying drugs among patients with multiple sclerosisCurr Med Res Opin201026366367420070144
   PubMed Web of Science ®Google Scholar
• SikkaRXiaFAubertREEstimating medication persistency using administrative claims dataAm J Manag Care200511744945716044982
   PubMed Web of Science ®Google Scholar
• AbdiHThe Bonferonni and Sidak corrections for multiple comparisonsSalkindNJEncyclopedia of measurement and statisticsThousand Oaks, CASAGE Publications, Inc2007103107
   Google Scholar
• AllisonPDSurvival analysis using SAS^® A practical guideCary, NCSAS Institute, Inc1995
   Google Scholar
• PortaccioEZipoliVSiracusaGSorbiSAmatoMPLong-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosisEur Neurol20085934131135
   Web of Science ®Google Scholar
• PattiFOptimizing the benefit of multiple sclerosis therapy: the importance of treatment adherencePatient Prefer Adherence201041920165593
   PubMed Web of Science ®Google Scholar
• PhillipsALIvanovaJIBergmanREBirnbaumHGStewartMMeleticheDMImpact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosisToronto, Ontario, Canada2010
   Google Scholar
• TanHYuJTabbyDDevriesASingerJClinical and economic impact of a specialty care management program among patients with multiple sclerosis: a cohort studyMult Scler201016895696320595246
   PubMed Web of Science ®Google Scholar
• GirouardNTheoretGManagement strategies for improving the tolerability of interferons in the treatment of multiple sclerosisCan J Neurosci Nurs2008304182519146204
   PubMedGoogle Scholar
• Biogen IdecServices and support. Avonex patient services Available from: http://www.avonex.com/service-and-support.xml. Accessed Dec 8 2010.
   Google Scholar
• Teva PharmaceuticalsShared solutions. Support, knowledge, answers for patients with MS using COPAXONE (glatiramer acetate injection) Available from: http://www.copaxone.com/supportServices/default.aspx. Accessed Dec 8 2010.
   Google Scholar
• EMD serono, Inc and Pfizer IncMS lifelines Available from: www.mslifelines.com. Accessed Dec 8 2010.
   Google Scholar
• Bayer Healthcare PharmaceuticalsBetaplus MS support group Available from: http://www.betaseron.com/patients/betaplus/about_betaplus.jsp. Accessed Dec 8 2010.
   Google Scholar
• SmrtkaJCaonCSaundersCBeckerBLBaxterNEnhancing adherence through educationJ Neurosci Nurs2010425 SupplS19S2921049830
   PubMed Web of Science ®Google Scholar
• SaundersCCaonCSmrtkaJShoemakerJFactors that influence adherence and strategies to maintain adherence to injected therapies for patients with multiple sclerosisJ Neurosci Nurs2010425 SupplS10S1821049829
   PubMed Web of Science ®Google Scholar
• CaonCSaundersCSmrtkaJBaxterNShoemakerJInjectable disease-modifying therapy for relapsing-remitting multiple sclerosis: a review of adherence dataJ Neurosci Nurs2010425 SupplS5S921049828
   PubMed Web of Science ®Google Scholar
• CaonCSaundersCSmrtkaJIntroduction: adherence to disease-modifying therapies–key to optimizing outcomes in relapsing multiple sclerosisJ Neurosci Nurs2010425 SupplS1S421049827
   PubMed Web of Science ®Google Scholar